Teleflex Incorporated (NYSE:TFX) – Equities researchers at Jefferies Group lowered their Q3 2017 earnings per share estimates for shares of Teleflex in a research report issued on Thursday. Jefferies Group analyst R. Denhoy now anticipates that the medical technology company will post earnings per share of $1.99 for the quarter, down from their prior estimate of $2.03. Jefferies Group currently has a “Buy” rating and a $230.00 price objective on the stock. Jefferies Group also issued estimates for Teleflex’s FY2017 earnings at $8.22 EPS, Q1 2018 earnings at $2.12 EPS, Q2 2018 earnings at $2.39 EPS, Q3 2018 earnings at $2.44 EPS, Q4 2018 earnings at $2.70 EPS, FY2019 earnings at $10.98 EPS and FY2020 earnings at $12.39 EPS.
TFX has been the topic of several other research reports. Barclays PLC reissued a “buy” rating on shares of Teleflex in a research report on Monday, June 26th. Needham & Company LLC reissued a “buy” rating on shares of Teleflex in a research report on Friday, August 4th. Zacks Investment Research raised shares of Teleflex from a “hold” rating to a “buy” rating and set a $228.00 target price on the stock in a research report on Friday, June 23rd. Deutsche Bank AG lifted their target price on shares of Teleflex from $213.00 to $220.00 and gave the stock a “buy” rating in a research report on Monday, May 8th. Finally, BidaskClub cut shares of Teleflex from a “buy” rating to a “hold” rating in a research report on Monday, July 31st. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and six have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $221.17.
COPYRIGHT VIOLATION NOTICE: This article was originally published by Community Financial News and is the sole property of of Community Financial News. If you are viewing this article on another domain, it was stolen and reposted in violation of international copyright and trademark laws. The original version of this article can be accessed at https://www.com-unik.info/2017/08/19/jefferies-group-analysts-cut-earnings-estimates-for-teleflex-incorporated-nysetfx-updated.html.
Teleflex (NYSE:TFX) last announced its quarterly earnings results on Thursday, August 3rd. The medical technology company reported $2.04 earnings per share for the quarter, topping analysts’ consensus estimates of $1.91 by $0.13. The firm had revenue of $528.60 million for the quarter, compared to the consensus estimate of $518.98 million. Teleflex had a return on equity of 16.12% and a net margin of 12.36%. The business’s revenue was up 11.6% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.89 earnings per share.
The business also recently declared a quarterly dividend, which will be paid on Friday, September 15th. Stockholders of record on Tuesday, August 15th will be paid a dividend of $0.34 per share. The ex-dividend date is Friday, August 11th. This represents a $1.36 annualized dividend and a dividend yield of 0.64%. Teleflex’s payout ratio is currently 26.00%.
In related news, Director Gretchen R. Haggerty purchased 1,000 shares of the firm’s stock in a transaction dated Wednesday, June 21st. The stock was bought at an average price of $203.82 per share, for a total transaction of $203,820.00. Following the purchase, the director now directly owns 1,760 shares in the company, valued at approximately $358,723.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Stephen K. M.D. Klasko sold 200 shares of the firm’s stock in a transaction that occurred on Thursday, June 1st. The stock was sold at an average price of $199.93, for a total transaction of $39,986.00. Following the sale, the director now owns 8,080 shares of the company’s stock, valued at approximately $1,615,434.40. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 8,300 shares of company stock valued at $1,643,975. 2.39% of the stock is currently owned by company insiders.
Several large investors have recently modified their holdings of the company. UBS Asset Management Americas Inc. raised its stake in shares of Teleflex by 118.9% in the fourth quarter. UBS Asset Management Americas Inc. now owns 72,560 shares of the medical technology company’s stock valued at $11,692,000 after buying an additional 39,419 shares during the last quarter. Teachers Advisors LLC raised its stake in shares of Teleflex by 4.8% in the fourth quarter. Teachers Advisors LLC now owns 45,560 shares of the medical technology company’s stock valued at $7,342,000 after buying an additional 2,074 shares during the last quarter. Creative Planning raised its stake in shares of Teleflex by 3.7% in the first quarter. Creative Planning now owns 2,259 shares of the medical technology company’s stock valued at $438,000 after buying an additional 81 shares during the last quarter. Pennsylvania Trust Co raised its stake in shares of Teleflex by 0.7% in the first quarter. Pennsylvania Trust Co now owns 2,165 shares of the medical technology company’s stock valued at $419,000 after buying an additional 15 shares during the last quarter. Finally, Fox Run Management L.L.C. bought a new stake in shares of Teleflex during the first quarter valued at about $349,000. Institutional investors own 93.02% of the company’s stock.
Teleflex Incorporated is a provider of medical technology products. The Company designs, develops, manufactures and supplies single-use medical devices used by hospitals and healthcare providers for diagnostic and therapeutic procedures in critical care and surgical applications. The Company operates through six segments: Vascular North America; Anesthesia North America; Surgical North America; Europe, the Middle East and Africa (EMEA); Asia, and Original Equipment Manufacturer (OEM).
What are top analysts saying about Teleflex Incorporated? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Teleflex Incorporated and related companies.